Actemra SC Injection 162 mg/0.9 ml

Actemra/সিলিজুম্যাব Injection is a biologic medication containing Tocilizumab as its active ingredient. Manufactured by Roche Bangladesh Ltd, this 162 mg/0.9 ml subcutaneous injection treats autoimmune disorders like rheumatoid arthritis, COVID-19 complications, and cytokine release syndrome. Priced at ৳20,828.80 per unit, it requires strict storage at 2°C–8°C to maintain efficacy.

The drug works by inhibiting interleukin-6 (IL-6) receptors, reducing inflammation in conditions like RA, PJIA, and GCA. For COVID-19 patients, it controls life-threatening immune responses. Dosage varies by weight and condition—8 mg/kg IV for adults (≥30 kg) or 12 mg/kg for pediatric patients (<30 kg). Explore more about Tocilizumab.

Common side effects include infections, hypertension, and injection-site reactions. Drug interactions with CYP3A4 substrates (e.g., statins) necessitate caution. Pregnant or lactating women should use it only if benefits outweigh risks. For dosage forms, see SC Injection details.

• Storage: Refrigerate; avoid freezing.
• Pricing: ৳20,828.80 per vial.
• Alternatives: Actemra 80 mg/4 ml, Actemra 200 mg/10 ml.

Adults with RA: 4-8 mg/kg IV every 4 weeks. Pediatric PJIA/SJIA: 10-12 mg/kg based on weight. COVID-19: 8-12 mg/kg single/repeat dose. Dose reduction needed for liver toxicity or low blood cells. Use SC Injection weekly only for SSC-ILD.

Most common adverse reactions [incidence of at least 5%): upper respiratory tract infections, nasopharyngitis, headache, hypertension, increased ALT, injection site reactions. Most common adverse reactions in COVID-19 (incidence >3%) are constipation, anxiety, diarrhea, insomnia, hypertension and nausea.

Pregnancy Category C: Use only if benefits outweigh risks (fetal harm in animal studies). Discontinue breastfeeding – drug may secrete in milk. Risk-benefit assessment crucial in COVID-19 treatment.

Monitor for infections, monthly LFT and blood counts. Avoid in active tuberculosis. Do not administer live vaccines with tocilizumab. Use caution in patients with gastric ulcers.

Pediatric: Approved for PJIA/SJIA/CRS from age 2+. Geriatric: Higher infection risk. Hepatic/Renal: No dose change in moderate renal disease; limited data in severe cases.

In case of an overdose, it is recommended that the patient be monitored for signs and symptoms of adverse reactions. Patients who develop adverse reactions should receive appropriate symptomatic treatment.